Access to Emergency Medicine

Regulatory Comment Letters

• ACEP Response to Nondiscrimination in Health Programs – September 26, 2022
• ACEP Response to OSG Health Misinformation RFI – April 28, 2022
• ACEP Response to OSHA COVID-19 Emergency Temporary Standard – April 21, 2022
• ACEP and SAEM Comments on Draft CDC Opioid Guideline – April 11, 2022
• ACEP Response to DHS Public Charge Ground of Inadmissibility – March 30, 2022
• ACEP Response to OSTP Request for Information on Connected Health – March 25, 2022
• ACEP Response to National Health Security Strategy Request for Information – February 23, 2022
• ACEP and ACS Joint Letter Commenting on ASPR Draft Guidelines for Regional Health Care Emergency Preparedness and Response Systems – December 10, 2021
• ACEP Comments on FDA Essential Medications List – May 24, 2021
• ACEP Comments on HIPAA Proposed Rule – May 6, 2021
• Sign-on Letter to Acting HHS Secretary on Practice Guidelines for Prescribing Buprenorphine – January 27, 2021
• ACEP Response to DEA proposed rule on Registering EMS Agencies – December 4, 2020
• ACEP Response to DEA Electronic Prescribing Interim Final Rule – June 22, 2020
• ACEP Response to CDC Request for Information on Pain Management – June 16, 2020
• ACEP Response to Request for Information on the Strategic National Stockpile – May 29, 2020
• ACEP letter to Secretary Azar on Removing Barriers to OUD Treatment – May 26, 2020
• ACEP Response to Transparency in Coverage Proposed Rule – January 29, 2020 
• ACEP Comments on the DEA Proposed Rule on 2020 Controlled Substances Quotas – October 10, 2019
• ACEP Response to Ensuring Patient Access and Effective Drug Enforcement Request for Information – August 29, 2019
• ACEP Response to FCC Proposed Connected Care Pilot - August 27, 2019
• ACEP Response to Nondiscrimination in Health Proposed Rule – August 13, 2019
• ACEP Response to Draft Report on Pain Management Best Practices – April 1, 2019
• ACEP Comments on FDA Meeting on Drug Shortages – January 10, 2019
• ACEP Comments on IPI Drug Pricing Model – December 27, 2018
• ACEP Comments for FDA Public Meeting on Community Use of Naloxone – December 14, 2018
• ACEP Comments on Inadmissibility on Public Charge Grounds Proposed Rule – December 10, 2018
• ACEP Comments on FDA Proposed Rule on Bulk Drug Substances – November 5, 2018
• ACEP Comments on the DEA Proposed Rule on Controlled Substances Quotas – May 4, 2018
• ACEP Comments on the Protecting Statutory Conscience Rights in Health Care Proposed Rule – March 27, 2018